Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 305

1.

The EuroSIDA study: 25 years of scientific achievements.

Laut K, Kirk O, Rockstroh J, Phillips A, Ledergerber B, Gatell J, Gazzard B, Horban A, Karpov I, Losso M, d'Arminio Monforte A, Pedersen C, Ristola M, Reiss P, Scherrer AU, de Wit S, Aho I, Rasmussen LD, Svedhem V, Wandeler G, Pradier C, Chkhartishvili N, Matulionyte R, Oprea C, Kowalska JD, Begovac J, Miró JM, Guaraldi G, Paredes R, Raben D, Podlekareva D, Peters L, Lundgren JD, Mocroft A.

HIV Med. 2019 Oct 24. doi: 10.1111/hiv.12810. [Epub ahead of print]

PMID:
31647187
2.

"Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation".

Wareham NE, Li Q, Sengeløv H, Da Cunha-Bang C, Gustafsson F, Heilmann C, Perch M, Rasmussen A, Sørensen SS, Mocroft A, Lundgren JD.

J Cancer Res Clin Oncol. 2019 Dec;145(12):3125-3135. doi: 10.1007/s00432-019-03039-2. Epub 2019 Nov 5.

PMID:
31587105
3.

Abdominal adipose tissue is associated with alterations in tryptophan-kynurenine metabolism and markers of systemic inflammation in people with HIV.

Gelpi M, Ueland PM, Trøseid M, Mocroft A, Lebech AM, Ullum H, Midttun Ø, Lundgren J, Nielsen SD; Copenhagen Comorbidity in HIV Infection (COCOMO) Study.

J Infect Dis. 2019 Sep 20. pii: jiz465. doi: 10.1093/infdis/jiz465. [Epub ahead of print]

PMID:
31538186
4.

Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study.

Hatleberg CI, Ryom L, Kamara D, De Wit S, Law M, Phillips A, Reiss P, D'Arminio Monforte A, Mocroft A, Pradier C, Kirk O, Kovari H, Bonnet F, El-Sadr W, Lundgren JD, Sabin C; D:A:D Study Group.

EClinicalMedicine. 2019 Aug 11;13:91-100. doi: 10.1016/j.eclinm.2019.07.008. eCollection 2019 Aug.

5.

Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study.

Ryom L, Dilling Lundgren J, Reiss P, Kirk O, Law M, Ross M, Morlat P, Andreas Fux C, Fontas E, De Wit S, D'Arminio Monforte A, El-Sadr W, Phillips A, Ingrid Hatleberg C, Sabin C, Mocroft A; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group.

J Infect Dis. 2019 Oct 8;220(10):1629-1634. doi: 10.1093/infdis/jiz369.

PMID:
31504669
6.

Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus Treatment.

Mocroft A, Lundgren J, Gerstoft J, Rasmussen LD, Bhagani S, Aho I, Pradier C, Bogner JR, Mussini C, Uberti Foppa C, Maltez F, Laguno M, Wandeler G, Falconer K, Trofimova T, Borodulina E, Jevtovic D, Bakowska E, Kase K, Kyselyova G, Haubrich R, Rockstroh JK, Peters L; EuroSIDA Study .

Clin Infect Dis. 2019 Jul 2. pii: ciz601. doi: 10.1093/cid/ciz601. [Epub ahead of print]

PMID:
31504296
7.

Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study - 2012 - 2015.

Raben D, Sullivan AK, Mocroft A, Kutsyna G, Hadžiosmanović V, Vassilenko A, Chkhartisvili N, Mitsura V, Pedersen C, Anderson J, Begovac J, Bak Dragsted U, Bertisch B, Grzeszczuk A, Minton J, Necsoi VC, Kitchen M, Ajana F, Sokhan A, Comi L, Farazmand P, Pesut D, De Wit S, Gatell JM, Gazzard B, d'Arminio Monforte A, Rockstroh JK, Yazdanpanah Y, Champenois K, Jakobsen ML, Lundgren JD; HIDES Study Group.

PLoS One. 2019 Aug 13;14(8):e0220108. doi: 10.1371/journal.pone.0220108. eCollection 2019.

8.

Long-lasting alterations in adipose tissue density and adiponectin production in people living with HIV after thymidine analogues exposure.

Gelpi M, Knudsen AD, Larsen KB, Mocroft A, Lebech AM, Lindegaard B, Lundgren J, Kofoed KF, Nielsen SD; Copenhagen Comorbidity in HIV Infection (COCOMO) Study.

BMC Infect Dis. 2019 Aug 9;19(1):708. doi: 10.1186/s12879-019-4347-y.

9.

Serious clinical events in HIV-positive persons with chronic kidney disease.

Ryom L, Lundgren JD, Law M, Kirk O, El-Sadr W, Bonnet F, Weber R, Fontas E, Monforte AD, Phillips A, Reiss P, de Wit S, Hatleberg CI, Sabin C, Mocroft A; D:A:D study group.

AIDS. 2019 Nov 15;33(14):2173-2188. doi: 10.1097/QAD.0000000000002331.

PMID:
31385862
10.

Prevalence and risk factors of prolonged QT interval and electrocardiographic abnormalities in persons living with HIV.

Knudsen AD, Kofoed KF, Gelpi M, Sigvardsen PE, Mocroft A, Kühl JT, Fuchs A, Køber L, Nordestgaard BG, Benfield T, Graff C, Skov MW, Lundgren J, Nielsen SD; Copenhagen Comorbidity in HIV Infection (COCOMO) Study.

AIDS. 2019 Nov 15;33(14):2205-2210. doi: 10.1097/QAD.0000000000002327.

PMID:
31373917
11.

Development and Validation of a Risk Score for Febrile Neutropenia After Chemotherapy in Patients With Cancer: The FENCE Score.

Aagaard T, Roen A, Reekie J, Daugaard G, Brown PN, Specht L, Sengeløv H, Mocroft A, Lundgren J, Helleberg M.

JNCI Cancer Spectr. 2018 Nov 29;2(4):pky053. doi: 10.1093/jncics/pky053. eCollection 2018 Oct. Erratum in: JNCI Cancer Spectr. 2019 Apr 15;3(1):pkz009.

12.

Prevalence of impaired renal function in virologically suppressed people living with HIV compared with controls: the Copenhagen Comorbidity in HIV Infection (COCOMO) study.

Petersen N, Knudsen AD, Mocroft A, Kirkegaard-Klitbo D, Arici E, Lundgren J, Benfield T, Oturai P, Nordestgaard BG, Feldt-Rasmussen B, Nielsen SD, Ryom L.

HIV Med. 2019 Nov;20(10):639-647. doi: 10.1111/hiv.12778. Epub 2019 Jul 29.

PMID:
31359592
13.

Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe.

Neesgaard B, Pelchen-Matthews A, Ryom L, Florence E, Peters L, Roen A, Svedhem V, Clarke A, Benfield T, Mitsura V, Moreno S, Beniowski M, Begovac J, Matulionyte R, Trofimova T, Elbirt D, Kundro M, Vullo V, Behrens G, Staub T, Ragone L, Vannappagari V, Lundgren J, Mocroft A; EuroSIDA study.

AIDS. 2019 Nov 1;33(13):2013-2024. doi: 10.1097/QAD.0000000000002320.

PMID:
31335807
14.

Cervical cancer risk in women living with HIV across four continents: A multicohort study.

Rohner E, Bütikofer L, Schmidlin K, Sengayi M, Maskew M, Giddy J, Taghavi K, Moore RD, Goedert JJ, Gill MJ, Silverberg MJ, D'Souza G, Patel P, Castilho JL, Ross J, Sohn A, Bani-Sadr F, Taylor N, Paparizos V, Bonnet F, Verbon A, Vehreschild JJ, Post FA, Sabin C, Mocroft A, Dronda F, Obel N, Grabar S, Spagnuolo V, Quiros-Roldan E, Mussini C, Miro JM, Meyer L, Hasse B, Konopnicki D, Roca B, Barger D, Clifford GM, Franceschi S, Egger M, Bohlius J.

Int J Cancer. 2020 Feb 1;146(3):601-609. doi: 10.1002/ijc.32260. Epub 2019 Jun 19.

PMID:
31215037
15.

Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients.

Khurana MP, Lodding IP, Mocroft A, Sørensen SS, Perch M, Rasmussen A, Gustafsson F, Lundgren JD.

Open Forum Infect Dis. 2019 May 8;6(6):ofz215. doi: 10.1093/ofid/ofz215. eCollection 2019 Jun.

16.

Incidence Rates and Risk Factors of Clostridioides difficile Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients.

Ilett EE, Helleberg M, Reekie J, Murray DD, Wulff SM, Khurana MP, Mocroft A, Daugaard G, Perch M, Rasmussen A, Sørensen SS, Gustafsson F, Frimodt-Møller N, Sengeløv H, Lundgren J.

Open Forum Infect Dis. 2019 Feb 19;6(4):ofz086. doi: 10.1093/ofid/ofz086. eCollection 2019 Apr.

17.

Development and validation of a cycle-specific risk score for febrile neutropenia during chemotherapy cycles 2-6 in patients with solid cancers: The CSR FENCE score.

Aagaard T, Reekie J, Roen A, Daugaard G, Specht L, Sengeløv H, Mocroft A, Lundgren J, Helleberg M.

Int J Cancer. 2020 Jan 15;146(2):321-328. doi: 10.1002/ijc.32249. Epub 2019 Mar 28.

PMID:
30839100
18.

Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA.

Amele S, Peters L, Sluzhynska M, Yakovlev A, Scherrer A, Domingo P, Gerstoft J, Viard JP, Gisinger M, Flisiak R, Bhaghani S, Ristola M, Leen C, Jablonowska E, Wandeler G, Stellbrink H, Falconer K, D'Arminio Monforte A, Horban A, Rockstroh JK, Lundgren JD, Mocroft A; EuroSIDA study group.

HIV Med. 2019 Apr;20(4):264-273. doi: 10.1111/hiv.12711. Epub 2019 Feb 8.

PMID:
30734998
19.

Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial.

Bernardino JI, Mocroft A, Wallet C, de Wit S, Katlama C, Reiss P, Mallon PW, Richert L, Molina JM, Knobel H, Morlat P, Babiker A, Pozniac A, Raffi F, Arribas JR; NEAT001/ANRS143 Trial Study Group.

PLoS One. 2019 Jan 28;14(1):e0209911. doi: 10.1371/journal.pone.0209911. eCollection 2019.

20.

Prior exposure to thymidine analogs and didanosine is associated with long-lasting alterations in adipose tissue distribution and cardiovascular risk factors.

Gelpi M, Afzal S, Fuchs A, Lundgren J, Knudsen AD, Drivsholm N, Mocroft A, Lebech AM, Lindegaard B, Kühl JT, Sigvardsen PE, Køber L, Nordestgaard BG, Kofoed KF, Nielsen SD.

AIDS. 2019 Mar 15;33(4):675-683. doi: 10.1097/QAD.0000000000002119.

PMID:
30585844
21.

Variation in antiretroviral treatment coverage and virological suppression among three HIV key populations.

Laut KG, Shepherd L, Gottfredsson M, Sedlacek D, Knysz B, Begovac J, Radoi R, Schmied B, Chkhartishvili N, Florence E, Ristola M, Fätkenheuer G, Mulcahy F, Schmid P, Kuzovatova E, Paduta D, Smidt J, Domingo P, Szlávik J, Lundgren J, Mocroft A, Kirk O; EuroSIDA study group.

AIDS. 2018 Nov 28;32(18):2807-2819. doi: 10.1097/QAD.0000000000002035.

PMID:
30289816
22.

Diagnostic performance of clinical characteristics to detect airflow limitation in people living with HIV and in uninfected controls.

Ronit A, Benfield T, Mocroft A, Gerstoft J, Nordestgaard BG, Vestbo J, Nielsen SD; Copenhagen Co-morbidity in HIV Infection (COCOMO) Study Group.

HIV Med. 2018 Nov;19(10):751-755. doi: 10.1111/hiv.12669. Epub 2018 Aug 30.

PMID:
30160344
23.

Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort.

Pelchen-Matthews A, Ryom L, Borges ÁH, Edwards S, Duvivier C, Stephan C, Sambatakou H, Maciejewska K, Portu JJ, Weber J, Degen O, Calmy A, Reikvam DH, Jevtovic D, Wiese L, Smidt J, Smiatacz T, Hassoun G, Kuznetsova A, Clotet B, Lundgren J, Mocroft A; EuroSIDA study.

AIDS. 2018 Oct 23;32(16):2405-2416. doi: 10.1097/QAD.0000000000001967.

PMID:
30134296
24.

Impact of CMV PCR Blips in Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation.

Lodding IP, Mocroft A, da Cunha Bang C, Gustafsson F, Iversen M, Kirkby N, Perch M, Rasmussen A, Sengeløv H, Sørensen SS, Lundgren JD.

Transplant Direct. 2018 May 16;4(6):e355. doi: 10.1097/TXD.0000000000000787. eCollection 2018 Jun.

25.

Classification of death causes after transplantation (CLASS): Evaluation of methodology and initial results.

Wareham NE, Da Cunha-Bang C, Borges ÁH, Ekenberg C, Gerstoft J, Gustafsson F, Hansen D, Heilmann C, Helleberg M, Hillingsø J, Krohn PS, Lodding IP, Lund TK, Lundgren L, Mocroft A, Perch M, Petersen SL, Petruskevicius I, Rasmussen A, Rossing K, Rostved AA, Sengeløv H, Sørensen VR, Sørensen SS, Lundgren JD.

Medicine (Baltimore). 2018 Jul;97(29):e11564. doi: 10.1097/MD.0000000000011564.

26.

Brief Report: Prevalence of Peripheral Artery Disease Is Higher in Persons Living With HIV Compared With Uninfected Controls.

Knudsen AD, Gelpi M, Afzal S, Ronit A, Roen A, Mocroft A, Lundgren J, Nordestgaard B, Sillesen H, Lebech AM, Køber L, Kofoed KF, Nielsen SD.

J Acquir Immune Defic Syndr. 2018 Nov 1;79(3):381-385. doi: 10.1097/QAI.0000000000001795.

PMID:
29985264
27.

Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus-infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study.

Shepherd L, Ryom L, Law M, Petoumenos K, Hatleberg CI, d'Arminio Monforte A, Sabin C, Bower M, Bonnet F, Reiss P, de Wit S, Pradier C, Weber R, El-Sadr W, Lundgren J, Mocroft A; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group.

Clin Infect Dis. 2019 Feb 1;68(4):650-657. doi: 10.1093/cid/ciy508.

PMID:
29912335
28.

Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals.

Peters L, Laut K, Resnati C, Del Campo S, Leen C, Falconer K, Trofimova T, Paduta D, Gatell J, Rauch A, Lacombe K, Domingo P, Chkhartishvili N, Zangerle R, Matulionyte R, Mitsura V, Benfield T, Zilmer K, Khromova I, Lundgren J, Rockstroh J, Mocroft A; EuroSIDA Study Group.

AIDS. 2018 Sep 10;32(14):1995-2004. doi: 10.1097/QAD.0000000000001928.

29.

Cytomegalovirus (CMV) Disease Despite Weekly Preemptive CMV Strategy for Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation.

Lodding IP, da Cunha Bang C, Sørensen SS, Gustafsson F, Iversen M, Kirkby N, Perch M, Rasmussen A, Sengeløv H, Mocroft A, Lundgren JD.

Open Forum Infect Dis. 2018 Apr 17;5(5):ofy080. doi: 10.1093/ofid/ofy080. eCollection 2018 May.

30.

Associations between serum albumin and serious non-AIDS events among people living with HIV.

Ronit A, Hatleberg CI, Ryom L, Bonnet F, El-Sadr W, Reiss P, Weber R, Pradier C, De Wit S, Law M, d'Arminio Monforte A, Lundgren J, Mocroft A, Phillips AN, Sabin CA; D:A:D Study Group.

AIDS. 2018 Aug 24;32(13):1837-1848. doi: 10.1097/QAD.0000000000001900.

31.

Persistent disparities in antiretroviral treatment (ART) coverage and virological suppression across Europe, 2004 to 2015.

Laut K, Shepherd L, Radoi R, Karpov I, Parczewski M, Mussini C, Maltez F, Losso M, Chkhartishvili N, Elinav H, Kovari H, Blaxhult A, Zangerle R, Trofimova T, Inglot M, Zilmer K, Kuzovatova E, Staub T, Raben D, Lundgren J, Mocroft A, Kirk O, On Behalf Of The EuroSIDA Study Group.

Euro Surveill. 2018 May;23(21). doi: 10.2807/1560-7917.ES.2018.23.21.1700382.

32.

The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients.

Wareham NE, Mocroft A, Sengeløv H, Da Cunha-Bang C, Gustafsson F, Heilmann C, Iversen M, Kirkby NS, Rasmussen A, Sørensen SS, Lundgren JD; MATCH in PERSIMUNE study group.

J Cancer Res Clin Oncol. 2018 Aug;144(8):1569-1580. doi: 10.1007/s00432-018-2674-9. Epub 2018 May 26.

PMID:
29804164
33.

Cascade of care and factors associated with virological suppression among HIV-positive persons linked to care in the Test and Keep in Care (TAK) project.

Kowalska JD, Ankiersztejn-Bartczak M, Shepherd L, Mocroft A.

Infection. 2018 Aug;46(4):533-540. doi: 10.1007/s15010-018-1154-0. Epub 2018 May 21.

34.

Body Mass Index and the Risk of Serious Non-AIDS Events and All-Cause Mortality in Treated HIV-Positive Individuals: D: A: D Cohort Analysis.

Achhra AC, Sabin C, Ryom L, Hatleberg C, Antonella dʼAminio M, de Wit S, Phillips A, Pradier C, Weber R, Reiss P, El-Sadr W, Bonnet F, Mocroft A, Lundgren J, Law MG; D:A:D Study Group.

J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):579-588. doi: 10.1097/QAI.0000000000001722.

PMID:
29771788
35.

Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study.

Ryom L, Lundgren JD, El-Sadr W, Reiss P, Kirk O, Law M, Phillips A, Weber R, Fontas E, d' Arminio Monforte A, De Wit S, Dabis F, Hatleberg CI, Sabin C, Mocroft A; D:A:D study group.

Lancet HIV. 2018 Jun;5(6):e291-e300. doi: 10.1016/S2352-3018(18)30043-2. Epub 2018 May 3.

PMID:
29731407
36.

Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America.

Caro-Vega Y, Schultze A, W Efsen AM, Post FA, Panteleev A, Skrahin A, Miro JM, Girardi E, Podlekareva DN, Lundgren JD, Sierra-Madero J, Toibaro J, Andrade-Villanueva J, Tetradov S, Fehr J, Caylà J, Losso MH, Miller RF, Mocroft A, Kirk O, Crabtree-Ramírez B.

BMC Infect Dis. 2018 Apr 23;18(1):191. doi: 10.1186/s12879-018-3077-x.

37.

Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study.

Hatleberg CI, Ryom L, El-Sadr W, Mocroft A, Reiss P, De Wit S, Dabis F, Pradier C, d'Arminio Monforte A, Kovari H, Law M, Lundgren JD, Sabin CA; Data Collection of Adverse Events of Anti-HIV drugs (D:A:D) Study group.

J Int AIDS Soc. 2018 Mar;21(3). doi: 10.1002/jia2.25083.

38.

Higher Risk of Abdominal Obesity, Elevated Low-Density Lipoprotein Cholesterol, and Hypertriglyceridemia, but not of Hypertension, in People Living With Human Immunodeficiency Virus (HIV): Results From the Copenhagen Comorbidity in HIV Infection Study.

Gelpi M, Afzal S, Lundgren J, Ronit A, Roen A, Mocroft A, Gerstoft J, Lebech AM, Lindegaard B, Kofoed KF, Nordestgaard BG, Nielsen SD.

Clin Infect Dis. 2018 Aug 1;67(4):579-586. doi: 10.1093/cid/ciy146.

PMID:
29471519
39.

Airflow limitation in people living with HIV and matched uninfected controls.

Ronit A, Lundgren J, Afzal S, Benfield T, Roen A, Mocroft A, Gerstoft J, Nordestgaard BG, Vestbo J, Nielsen SD; Copenhagen Co-morbidity in HIV infection (COCOMO) study group.

Thorax. 2018 May;73(5):431-438. doi: 10.1136/thoraxjnl-2017-211079. Epub 2018 Jan 13.

PMID:
29331988
40.

Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA study.

Peters L, Mocroft A, Grint D, Moreno S, Calmy A, Jevtovic D, Sambatakou H, Lacombe K, De Wit S, Rockstroh J, Smidt J, Karpov I, Grzeszczuk A, Haziosmanovic V, Gottfredsson M, Radoi R, Kuzovatova E, Orkin C, Ridolfo AL, Zapirain J, Lundgren J.

Antivir Ther. 2018;23(5):405-413. doi: 10.3851/IMP3218.

PMID:
29303483
41.

Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort.

Roen A, Laut K, Pelchen-Matthews A, Borodulina E, Caldeira L, Clarke A, Clotet B, d'Arminio Monforte A, Fätkenheuer G, Gatell Artigas JM, Karpov I, Kuznetsova A, Kyselyova G, Mozer-Lisewska I, Mulcahy F, Ragone L, Scherrer A, Uzdaviniene V, Vandekerckhove L, Vannappagari V, Ostergaard L, Mocroft A; EuroSIDA study.

HIV Med. 2018 Apr;19(4):252-260. doi: 10.1111/hiv.12573. Epub 2017 Dec 22.

PMID:
29271606
42.

Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma.

Shepherd L, Ryom L, Law M, Hatleberg CI, de Wit S, Monforte AD, Battegay M, Phillips A, Bonnet F, Reiss P, Pradier C, Grulich A, Sabin C, Lundgren J, Mocroft A.

J Natl Cancer Inst. 2018 Jun 1;110(6):598-607. doi: 10.1093/jnci/djx249.

43.

Contemporary protease inhibitors and cardiovascular risk.

Lundgren J, Mocroft A, Ryom L.

Curr Opin Infect Dis. 2018 Feb;31(1):8-13. doi: 10.1097/QCO.0000000000000425. Review.

PMID:
29232276
44.

Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study.

Boyd MA, Mocroft A, Ryom L, Monforte AD, Sabin C, El-Sadr WM, Hatleberg CI, De Wit S, Weber R, Fontas E, Phillips A, Bonnet F, Reiss P, Lundgren J, Law M.

PLoS Med. 2017 Nov 7;14(11):e1002424. doi: 10.1371/journal.pmed.1002424. eCollection 2017 Nov.

45.

Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?

Mocroft A, Laut K, Reiss P, Gatell J, Ormaasen V, Cavassini M, Hadziosmanovic V, Mansinho K, Pradier C, Vasylyev M, Mitsura V, Vandekerckhove L, Ostergaard L, Clarke A, Degen O, Mulcahy F, Castagna A, Sthoeger Z, Flamholc L, Sedláček D, Mozer-Lisewska I, Lundgren JD; EuroSIDA Study.

AIDS. 2018 Jan 14;32(2):205-215. doi: 10.1097/QAD.0000000000001684.

PMID:
29112060
46.

Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study.

Efsen AMW, Schultze A, Miller RF, Panteleev A, Skrahin A, Podlekareva DN, Miro JM, Girardi E, Furrer H, Losso MH, Toibaro J, Caylà JA, Mocroft A, Lundgren JD, Post FA, Kirk O; TB: HIV study in EuroCoord.

J Infect. 2018 Jan;76(1):44-54. doi: 10.1016/j.jinf.2017.10.007. Epub 2017 Oct 20.

47.

Abacavir use and risk of recurrent myocardial infarction.

Sabin CA, Ryom L, d'Arminio Monforte A, Hatleberg CI, Pradier C, El-Sadr W, Kirk O, Weber R, Phillips AN, Mocroft A, Bonnet F, Law M, de Wit S, Reiss P, Lundgren JD; D:A:D Study Group.

AIDS. 2018 Jan 2;32(1):79-88. doi: 10.1097/QAD.0000000000001666.

PMID:
29028664
48.

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens.

Cozzi-Lepri A, Zangerle R, Machala L, Zilmer K, Ristola M, Pradier C, Kirk O, Sambatakou H, Fätkenheuer G, Yust I, Schmid P, Gottfredsson M, Khromova I, Jilich D, Flisiak R, Smidt J, Rozentale B, Radoi R, Losso MH, Lundgren JD, Mocroft A; EuroSIDA Study Group.

HIV Med. 2018 Feb;19(2):102-117. doi: 10.1111/hiv.12557. Epub 2017 Oct 6.

49.

The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people.

Shepherd L, Borges ÁH, Harvey R, Bower M, Grulich A, Silverberg M, Weber J, Ristola M, Viard JP, Bogner JR, Gargalianos-Kakolyris P, Mussini C, Mansinho K, Yust I, Paduta D, Jilich D, Smiatacz T, Radoi R, Tomazic J, Plomgaard P, Frikke-Schmidt R, Lundgren J, Mocroft A; EuroSIDA in EuroCOORD.

HIV Med. 2018 Feb;19(2):90-101. doi: 10.1111/hiv.12546. Epub 2017 Aug 31.

PMID:
28857427
50.

Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial.

Achhra AC, Mocroft A, Ross M, Ryom-Nielson L, Avihingsanon A, Bakowska E, Belloso W, Clarke A, Furrer H, Lucas GM, Ristola M, Rassool M, Ross J, Somboonwit C, Sharma S, Wyatt C.

Int J Antimicrob Agents. 2017 Sep;50(3):453-460. doi: 10.1016/j.ijantimicag.2017.04.021. Epub 2017 Jun 28.

Supplemental Content

Loading ...
Support Center